RESEARCH

Risk factors that affect the degree of bronchopulmonary dysplasia in very preterm infants: a 5-year retrospective study

Tingting Yang1,2, Qianqian Shen2,3, Siyu Wang6, Tianfang Dong1,2, Liang Liang1,2, Fan Xu2,5, Youfang He1,2, Chunlei Li1,2, Fang Luo1,2, Jiahong Liang1,2, Chunhui Tang2,6* and Jinghui Yang2,6,7*

Abstract

Background: Bronchopulmonary dysplasia (BPD) is one of the most common adverse consequences of premature delivery and the most common chronic lung disease in infants. BPD is associated with long-term lung diseases and neurodevelopmental disorders that can persist into the adulthood. The adverse consequences caused by severe BPD are more serious. However, there were few studies on the risk factors for severe BPD.

Methods: This is a retrospective study of preterm infants born less than 32-week gestational age (GA) and diagnosed with BPD.

Results: A total of 250 preterm infants with a diagnosis of BPD and GA < 32 weeks were included (137 boys [54.8%] and 113 girls [45.2%]). The birth weight ranged from 700 g to 2010 g and the mean birth weight was 1318.52 g (255.45 g). The GA ranged from 25 weeks to 31 weeks and 6 days (mean, 30 weeks). The number of cases of mild, moderate and severe BPD were 39 (15.6%), 185 (74.0%) and 26 (10.4%), respectively. There were significant differences in the rate of small for gestational age (SGA), intrauterine asphyxia, pulmonary hemorrhage, neonatal respiratory distress syndrome (NRDS), circulatory failure, pulmonary hypertension, patent ductus arteriosus (PDA), pulmonary surfactant (PS), aminophylline, caffeine, glucocorticoids, tracheal intubation, diuretics, and parenteral nutrition length among the three groups (P < 0.05). The time of parenteral nutrition (aOR = 3.343, 95% CI: 2.198 ~ 5.085) and PDA (aOR = 9.441, 95% CI: 1.186 ~ 75.128) were independent risk factors for severe BPD compared with mild BPD. PDA (aOR = 5.202, 95% CI: 1.803 ~ 15.010) and aminophylline (aOR = 6.179, 95% CI: 2.200 ~ 17.353) were independent risk factors for severe BPD, while caffeine (aOR = 0.260, 95% CI: 0.092 ~ 0.736) was the protective factor for severe BPD compared with moderate BPD. The time of parenteral nutrition (aOR = 2.972, 95% CI: 1.989 ~ 4.440) and caffeine (aOR = 4.525, 95% CI: 1.042 ~ 19.649) were independent risk factors for moderate BPD compared with mild BPD. Caffeine (aOR = 3.850, 95% CI: 1.358 ~ 10.916) was the independent risk factor for moderate BPD, while PDA (aOR = 0.192, 95% CI: 0.067 ~ 0.555) and aminophylline (aOR = 0.162, 95% CI: 0.058 ~ 0.455) were protective factors for moderate BPD compared with severe BPD. The time of parenteral nutrition (aOR = 0.337, 95% CI: 0.225 ~ 0.503) and caffeine (aOR = 0.221, 95% CI: 0.051 ~ 0.960) were protective factors for mild BPD compared with moderate BPD. The time of parenteral nutrition (aOR = 0.299, 95% CI: 0.197 ~ 0.455) and PDA (aOR = 0.106, 95% CI: 0.013 ~ 0.843) were protective factors for mild BPD compared with severe BPD.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

BPD is a chronic lung disease. Northway [1] reported BPD for the first time in 1967. However, the definition and characteristics of BPD have changed over the past several decades [1, 2]. The new definition of BPD is more comprehensive, with oxygen support at least 28 days as required, and includes a classification of severity. Infants born at GA < 32 weeks were classified as mild (no need for oxygen), moderate (21 to 30%) or severe BPD (> 30% or positive pressure assistance) based on the required fraction of inspired oxygen (FiO2) at 36 weeks of corrected GA [2].

In recent few decades, due to the development of perinatology and neonatal care, such as prenatal corticosteroids and exogenous PS treatment, the survival rate of premature infants has dramatically increased. The incidence of many complications related to premature delivery, such as NRDS, ventricular hemorrhage and necrotizing enterocolitis (NEC), has decreased. However, BPD remains one of the most common complications in preterm infants [3, 4]. Moreover, the incidence rate of BPD is becoming higher and higher, probably due to the increasing survival rate of very preterm infants [5]. According to the studies of different neonatal networks in many countries including the United States, Canada, South Korea, China and India, the incidence rate of BPD varies greatly, ranging from 11 to 50%, because of different diagnostic and management criteria [6]. The incidence rate of BPD increases with the decrease of GA or birth weight. About 30% of very low birth weight premature infants suffer from BPD [7]. The previous studies has reported that the incidence rate of BPD in preterm infants with GA < 32 weeks fluctuated from 12.9 to 41% [8]. About 40 ~ 50% of extremely premature infants suffer from BPD [4, 9], and the incidence rate of preterm infants with GA < 25 weeks is as high as 80% [10].

Newborns suffering from BPD have higher mortality [11] and incidence of pulmonary, cardiovascular, and neurodevelopmental disorders, leading to lower quality of life and increased resource utilization [12, 13]. Premature infants with severe BPD are particularly difficult to manage and are more prone to a variety of complications and comorbidities, including prolonged hospitalization, requirement of family respiratory support and higher death risk [14, 15]. The mortality of premature infants with severe BPD is 25%, and the readmission rate of surviving premature infants in the first year is as high as 50%. The incidence of neurodevelopmental disorder is 2-3 times higher than that of normal infants, which has become one of the important factors affecting the quality of life of surviving premature infants. Therefore, it’s particularly important to avoid severe BPD.

In the past few decades, many clinical prediction models have been reported. As we know, the smaller GA or birth weight, the higher the incidence of BPD. Other perinatal factors affecting BPD include gender [16], intrauterine growth retardation [17], chorioamnionitis [18], smoking [19], and race/nation [17]. Some postnatal factors also raise the risk of BPD and adverse outcomes such as NRDS, pulmonary inflammation, pulmonary vascular disease, infection, PDA, undernutrition and the need for invasive mechanical ventilation [20]. However, most studies focused on the pathogenesis and clinical risk factors of BPD, and there are few studies on the risk factors that affect the occurrence of different degrees of BPD. It is still not clear whether the above factors would increase the incidence of moderate or severe BPD. Early detection of risk factors may avoid the occurrence of moderate or severe BPD in the near future and reduce its long-term negative effects. Therefore, we put forward a hypothesis: the risk factors affecting the severity of BPD can be obtained by comparing the prenatal and postnatal conditions of preterm infants with mild, moderate and severe BPD, so as to guide clinical treatment and avoid moderate or severe BPD.

This study analyzed the sociodemographic data, perinatal factors, treatment and complications of premature infants with different degrees of BPD to find out the risk factors affecting the severity of BPD.

Methods

Study design and participants

This is a retrospective study. All clinical data of premature infants with GA < 32 weeks admitted to the First People’s Hospital of Yunnan Province from January 1, 2016 to December 31, 2020 were collected. Preterm infants with severe malformations, chromosomal abnormalities, genetic metabolic diseases or incomplete information...
were excluded. Premature infants with GA < 32 weeks who were diagnosed with BPD were included and divided into three groups according to the severity of BPD.

Study factors
We selected the possible risk factor variables according to previous studies. All methods were in accordance with relevant guidelines and provisions. The following data were collected:

1. Sociodemographic variables and perinatal factors: gender, GA, birth weight, intrauterine asphyxia, amniotic fluid pollution, placental abruption, premature rupture of membranes (PROM), maternal age, prenatal use of glucocorticoids, gestational diabetes mellitus (GDM), hypertensive disorder complicating pregnancy (HDCP), hyperthyroidism, hypothyroidism, maternal anemia, prenatal fever.

2. Complications: septicemia, sepsis, pneumonia, infection, NEC, apnea, respiratory failure, pulmonary hemorrhage, acute respiratory distress syndrome (ARDS), NRDS, circulatory failure, anemia, pulmonary hypertension, PDA, hypoproteinemia, electrolyte disorder, retinopathy of prematurity (ROP), intraventricular hemorrhage, intracranial hemorrhage, and paraventricular leukomalacia.

3. Treatment: PS, aminophylline, caffeine, glucocorticoid hormones, diuretics, noninvasive assisted ventilation, tracheal intubation, parenteral nutrition, FiO2.

Diagnostic criteria

1. Pulmonary hypertension: Pulmonary hypertension was diagnosed by echocardiograms and all newborns have echocardiograms within the first week after birth. Pulmonary artery systolic pressure higher than 35 mmHg was diagnosed as pulmonary hypertension.

2. Asphyxia: 1) The umbilical cord blood pH < 7.15; 2) Apgar score at 1 min or 5 min was less than 7 points. If the 5-min Apgar score was less than 7, the resuscitation measures were continued for 20 min, meanwhile, the Apgar scores were measured every 5 min; 3) Indications of neonatal neurological symptoms, such as seizures, coma, or hypotonia; and 4) Excluding asphyxiation from other causes.

3. PDA: The diagnosis mainly depends on echocardiography. Preterm infants have echocardiographic examinations within the first week after birth.

Ethics
This study was approved by the Ethics committee of The First People's Hospital of Yunnan Province (Ethic number: KHLL2021-KY001). Informed consent was waived due to the retrospective nature of this study.

Statistical analysis
SPSS 26.0 software was used for statistical analysis. The Chi-square test or Fisher exact test was used to analyze categorical variables. Continuous data with a normal distribution was described as mean and standard deviation and was analyzed by one-way analysis of variance. Continuous data that did not conform to a normal distribution was presented as the median [25th percentile, 75th percentile] and compared among groups by Kruskal-Wallis H test. Multivariate regression model was used for statistically significant variables in single factor stepwise analysis process. The final selected factors were used as hybrid factors to calculate the adjusted advantage ratio, the maximum likelihood ratio and the corresponding 95% confidence interval. All hypothesis tests were double-tailed, \( P < 0.05 \) was statistically significant. G*Power (version: 3.1.9.7) was used to calculate sample size and power value.

Results
All clinical data of 3494 premature infants admitted to the First People's Hospital of Yunnan Province from January 1, 2016 to December 31, 2020 were collected, including 477 premature infants with GA < 32 weeks. As a result, 250 premature infants with GA < 32 weeks diagnosed with BPD were included (Fig. 1). Among the 250 very preterm infants with BPD, 137(54.8%) were male and 113(45.2%) were female. The average birth weight was 1318.52 g (ranging from 700 g to 2010 g). The median of GA was 30 weeks (ranging from 25 weeks to 31+6 weeks). Among 250 cases of very preterm infants diagnosed with BPD, there were 23(9.2%) with GA < 28 weeks, 96 (38.4%) with 28 ~ 29+6 weeks, and 131(52.4%) with 30 ~ 31+6 weeks.

The antenatal features and demographic of very premature infants with different degrees of BPD were summarized (Table 1). The significant differences were observed in the rates of SGA and intrauterine asphyxia among the three groups \( (P < 0.05) \). There were no significant differences in the rates of male, GA, placental abruption, PROM, amniotic fluid pollution, maternal age ≥ 35 years, HDCP, GDM, hypothyroidism, hyperthyroidism, anemia, prenatal fever and prenatal use of glucocorticoids.

The complications of very premature infants with different degrees of BPD were summarized (Table 2). The differences of the rates of pulmonary hemorrhage, NRDS,
circulatory failure, pulmonary hypertension and PDA were statistically significant among the three groups ($P < 0.05$). And the rates of septicemia, sepsis, pneumonia, infection, NEC, apnea, respiratory failure, ARDS, anemia, hypoproteinemia, electrolyte disturbance, ROP, intraventricular hemorrhage, intracranial hemorrhage, and paraventricular leukomalacia were not significant different.

Treatment were also compared (Table 3). The use of PS, aminophylline, caffeine, glucocorticoids, tracheal intubation, diuretics, and parenteral nutrition were statistically significant among the three groups ($P < 0.05$). There were no significant differences in the maximum FiO$_2$ ≥ 40% or noninvasive assisted ventilation.

In the univariate analysis, 14 variables were statistically significant. Then multivariate logistic regression analysis was used because the data among the three groups did not meet the parallel test. The time of parenteral nutrition and PDA were independent risk factors for severe BPD compared with mild BPD. PDA and aminophylline were independent risk factors for severe BPD, while caffeine was the protective factor for severe BPD compared with moderate BPD. The time of parenteral nutrition and caffeine were independent risk factors for moderate BPD compared with mild BPD. Caffeine was the independent risk factor for moderate BPD, while PDA and aminophylline were protective factors for moderate BPD compared with severe BPD. The time of parenteral nutrition and caffeine were protective factors for mild BPD compared with moderate BPD. The time of parenteral nutrition and PDA were protective factors for mild BPD compared with severe BPD (Table 4).

**Discussion**

We found that the time of parenteral nutrition was the risk factor of moderate and severe BPD, PDA and aminophylline were risk factors for severe BPD, the role of caffeine in the severity of BPD was uncertain, and SGA was not related to the severity of BPD.

There was no significant difference in GA among the three groups of preterm infants with different degrees of BPD, but the rate of SGA was statistically significant, suggesting that there may have high incidence of growth retardation in the moderate or severe BPD group. Some studies have shown that fetal growth retardation raised the risk of BPD in premature infants [17, 21]. Similarly, there are evidences suggesting that SGA preterm neonates were considered to have higher risk of BPD compared to appropriate for GA neonates [22]. It was reported that SGA birth was associated with severity of
BPD [23] and SGA was one of the significant risk factors for moderate or severe BPD [24]. Our study results have showed that the rate of SGA was not related to the severity of BPD, which differs from the previous studies. However, it was concluded that the risk for neonatal adverse outcome associated with SGA varies by GA [24, 25]. It can explain why the rate of SGA is not related to the severity of BPD in our study because of the low enrollment of extremely premature infants.

In our study, extremely premature infants accounted for only 9.2% maybe due to lower live-birth ratio and higher post-natal mortality in extremely premature infants. A recent study by Chinese scholars have shown only 241(20.7%) survived of the 1163 extremely premature infants, while 849(73.0%) died in the delivery room and 73(6.3%) died in the neonatal intensive care unit [26]. In our another six-year retrospective study, among 3948 hospitalized premature infants, there were only 43(1.1%) cases of extremely premature infants, 3(7.0%) cases of whom died in the neonatal intensive care unit. Besides, it may be related to high rate of giving up treatment. It was reported that 862 (74.1%) of 1163 extremely premature infants died from withholding or withdrawal of care [26]. In the future, the improvement of perinatal and neonatal care can lead to a high survival rate of extremely premature infants and the correlation between GA and severity of BPD may be described more accurately. It is necessary to have a multi-center, large sample from the real-world to find the relationship between GA and the severity of BPD.

Our data showed that the time of parenteral nutrition was an independent risk factor for moderate or severe BPD. Premature infants usually cannot tolerate enteral feeding well [27], they rely on parenteral nutrition to meet the energy demand and the optimal growth and development in the first week after birth. Parenteral nutrition is a common clinical practice, which can provide some short-term development benefits for premature infants. However, parenteral nutrition is lower caloric intake, while higher fluid intake compared with enteral feeding [28]. As is known, early nutritional support may avoid severe BPD, but low caloric intake and high fluid intake are related to the severity of BPD [29]. Our finding was consistent with previous studies. Further well-designed prospective cohort studies may better demonstrate the relationship between parental nutrition duration and the severity of BPD.

PDA is an important risk factor for BPD [27]. However, there are few studies about PDA is associated with the severity of BPD. Our results suggested that PDA

### Table 1 Demographic features of preterm infants with different levels of BPD

| Variables                          | Mild BPD (n = 39) | Moderate BPD (n = 185) | Severe BPD (n = 26) | χ²/H/F/P |
|-----------------------------------|------------------|------------------------|---------------------|----------|
| Male (n, %)                       | 23 (58.9)        | 98 (52.9)              | 16 (61.5)           | 1.000    |
| GA (weeks, M(P25,P75))            | 30.1 (29.7,31.0) | 30.0 (28.8,30.8)       | 29.9 (28.4,31.0)    | 2.291c   |
| SGA (n, %)                        | 1 (2.6)          | 15 (8.1)               | 5 (19.2)            | 5.218    |
| Birth weight (g, mean±S)          | 1471.5 ± 213.5   | 1308.7 ± 246.3         | 1158.8 ± 265.5      | 13.431d  |
| Asphyxia (n, %)                   | 13 (33.3)        | 87 (47.0)              | 19 (73.0)           | 9.793    |
| Placental abruption (n, %)        | 0 (0)            | 4 (2.1)                | 0 (0)               | 0.043    |
| PROM (n, %)                       | 17 (43.5)        | 82 (44.3)              | 13 (50)             | 0.324    |
| Amniotic fluid contamination (n, %)| 0 (0)            | 1 (0.5)                | 1 (3.8)             | 2.378    |
| Maternal Age ≥ 35years (n, %)     | 9 (23.0)         | 45 (24.3)              | 10 (38.4)           | 2.547    |
| HDCP (n, %)                       | 6 (15.3)         | 40 (21.6)              | 7 (26.9)            | 0.111    |
| GDM (n, %)                        | 9 (23.0)         | 50 (27.0)              | 5 (19.2)            | 0.882    |
| Hyperthyroidism (n, %)            | 0 (0)            | 4 (2.1)                | 0 (0)               | 0.043    |
| Hypothyroidism (n, %)             | 2 (5.1)          | 12 (6.4)               | 5 (19.2)            | 4.356    |
| Anemia (n, %)                     | 3 (7.6)          | 6 (3.2)                | 1 (3.8)             | 1.396    |
| Antenatal fever (n, %)            | 1 (2.5)          | 6 (3.2)                | 0 (0)               | 0.230    |
| Use of glucocorticoids (n, %)     | 3 (7.6)          | 11 (5.9)               | 2 (7.6)             | 0.236    |

GA Gestational age, GDM Gestational diabetes mellitus, HDCP Hypertensive disorder complicating pregnancy, PROM Premature rupture of membranes, SGA Small for gestational age

*Fisher’s exact probability method

# Pearson’s chi-square value

* Kruskal-Wallis test

# One-way ANOVA, the rest using chi-square test

# H value

# F value, the rest are χ² values
was one of risk factors for severe BPD. Similarly, some studies have shown that PDA is a significant risk factor for developing moderate or severe BPD [24]. Besides, both medical and surgical therapies for PDA are associated with severe BPD [30, 31]. In our study, all preterm infants with PDA were treated conservatively or with medication. It is necessary to carry out a multi-center and large sample research to obtain the relationship between PDA and the severity of BPD, and pay more attention to the treatments of PDA.

Table 2  Complications of preterm infants with different levels of BPD

| Variables                              | Mild BPD (n = 39) | Moderate BPD (n = 185) | Severe BPD (n = 26) | \( \chi^2 \) | P     |
|----------------------------------------|-------------------|------------------------|---------------------|-------------|-------|
| Septicemia (n, %)                      | 0 (0)             | 3 (1.6)                | 1 (3.8)             | 1.435       | 0.231 |
| Sepsis (n, %)                          | 2 (5.1)           | 28 (15.1)              | 6 (23.0)            | 4.944       | 0.084*|
| NEC (n, %)                             | 1 (2.5)           | 6 (3.2)                | 1 (3.8)             | 0.087       | 0.769*|
| Infection (n, %)                       | 18 (46.1)         | 115 (62.1)             | 14 (53.8)           | 3.701       | 0.157 |
| Pneumonia (n, %)                       | 21 (53.8)         | 98 (52.9)              | 10 (38.4)           | 2.016       | 0.365 |
| Apnea (n, %)                           | 4 (10.2)          | 38 (20.5)              | 7 (26.9)            | 3.149       | 0.207 |
| Respiratory failure (n, %)             | 0 (0)             | 7 (3.7)                | 2 (7.6)             | 2.718       | 0.099 |
| Pulmonary hemorrhage (n, %)            | 1 (2.5)           | 19 (10.2)              | 10 (38.4)           | 17.052      | <0.001*|
| NRDS (n, %)                            | 7 (17.9)          | 81 (43.7)              | 19 (73.0)           | 19.647      | <0.001|
| ARDS (n, %)                            | 0 (0)             | 2 (1.0)                | 0 (0)               | 0.021       | 0.884*|
| Circulatory Failure (n, %)             | 0 (0)             | 28 (15.1)              | 6 (23.0)            | 13.460      | 0.001*|
| Pulmonary hypertension (n, %)          | 0 (0)             | 0 (0)                  | 1 (3.8)             | 4.301       | 0.038*|
| Anemia (n, %)                          | 35 (89.7)         | 165 (89.1)             | 26 (100.0)          | 5.569       | 0.062*|
| PDA (n, %)                             | 5 (12.8)          | 53 (28.6)              | 12 (46.1)           | 8.746       | 0.013 |
| Hypoproteinemia (n, %)                 | 21 (53.8)         | 116 (62.7)             | 20 (76.9)           | 3.566       | 0.168 |
| Electrolyte disorders (n, %)           | 17 (43.5)         | 86 (46.4)              | 17 (65.3)           | 3.622       | 0.164 |
| ROP (n, %)                             | 6 (15.3)          | 40 (21.6)              | 4 (15.3)            | 1.169       | 0.557 |
| Paraventricular white matter softening (n, %) | 1 (2.5)          | 3 (1.6)                | 0 (0)               | 0.617       | 0.432*|
| Intraventricular hemorrhage (n, %)     | 0 (0)             | 1 (0.5)                | 0 (0)               | 0.011       | 0.918*|
| Intracranial hemorrhage (n, %)         | 7 (17.9)          | 44 (23.7)              | 7 (26.9)            | 0.841       | 0.657 |

Table 3  Treatment in preterm infants with different levels of BPD

| Variables                              | Mild BPD (n = 39) | Moderate BPD (n = 185) | Severe BPD (n = 26) | \( \chi^2/H \) | P     |
|----------------------------------------|-------------------|------------------------|---------------------|-------------|-------|
| PS (n, %)                              | 6 (15.3)          | 85 (45.9)              | 19 (73.0)           | 22.166      | <0.001*|
| Aminophylline (n, %)                   | 4 (10.2)          | 20 (10.8)              | 11 (42.3)           | 14.522      | 0.001*|
| Caffeine (n, %)                        | 15 (0.38)         | 128 (69.1)             | 11 (42.3)           | 17.423      | <0.001*|
| Glucocorticoids (n, %)                 | 37 (94.8)         | 140 (75.6)             | 26 (100.0)          | 20.606      | <0.001*|
| Non-invasive respiratory support (n, %) | 37 (94.8)         | 180 (97.2)             | 26 (100.0)          | 1.532       | 0.217*|
| Invasive respiratory support (n, %)    | 10 (25.6)         | 111 (60.0)             | 21 (80.7)           | 22.291      | <0.001*|
| Maximum FiO2 ≥ 40% (n, %)             | 24 (61.5)         | 131 (70.8)             | 22 (84.6)           | 4.019       | 0.134*|
| Parenteral nutrition (days,M(P25,P75))a| 10 (8,12)         | 17 (15,20)             | 19 (16,22)          | 82.257      | <0.001|
| Diuretics (n, %)                       | 19 (48.7)         | 50 (27.0)              | 15 (57.6)           | 14.342      | 0.001*|

FiO2: Fraction of inspired oxygen, PS: Pulmonary Surfactant
*A Fisher’s exact probability method
*B Pearson’s chi-square value
*C Kruskal-Wallis test, the rest using chi-square test
*H value, the rest are \( \chi^2 \) values
Our results suggested that caffeine was a protective factor that can prevent very preterm infants from developing into severe BPD, while caffeine was one of the independent risk factors for moderate BPD. The role of caffeine in the severity of BPD was uncertain. Caffeine treatment test of premature infants with apnea confirmed that caffeine significantly reduced the occurrence of BPD [32, 33], and most data [32, 34] supported that caffeine could alleviate the severity of BPD. Moreover, the preventive effect of caffeine on moderate or severe BPD was related to its dosage [35]. Infants in the high dosage group had lower odds of developing moderate or severe BPD compared with the lower dosage group [35]. The dosage of caffeine was not included in our study, which may explain why the role of caffeine in the severity of BPD was uncertain. Large prospective studies are needed to determine the relationship between caffeine and the severity of BPD, and the dosage of caffeine should be pay more attention to.

Our study has some advantages. Multiple variables were studied including detailed maternal-antenatal pathology, such as HDCP, diabetes and thyroid status. Besides, all data came from real-world. Our results suggested that the time of parenteral nutrition was one of risk factors of moderate and severe BPD, PDA and aminophylline were risk factors for severe BPD, the role of caffeine in the severity of BPD was uncertain, and SGA was not related to the severity of BPD. However, there are limitations. First, this is a retrospective study and our data may be biased. Secondly, it is a single-center study of preterm infants (GA < 32 weeks) born in Yunnan province in China and the results should be carefully applied in other regions or country. It is necessary to have a multi-center, large sample from the real-world to obtain the relationship between SGA of BPD. Further well-designed prospective cohort researches are also needed to confirm the association between caffeine, aminophylline, parenteral nutrition duration and the severity of BPD.

**Table 4 Correlative factors of BPD with different degrees**

| Correlative factors for mild BPD | β     | SE   | Wald  | aOR  | 95% CI       | P   |
|---------------------------------|-------|------|-------|------|--------------|-----|
| Compared with moderate BPD group | PN (days) | −1.089 | 0.205 | 28.281 | 0.337 | 0.225~0.503 | <0.001 |
| Caffeine                         | −1.510 | 0.749 | 4.059 | 0.221 | 0.051~0.960 | 0.044 |
| Compared with severe BPD group   | PN (days) | −1.207 | 0.214 | 31.823 | 0.299 | 0.197~0.455 | <0.001 |
| PDA                              | −2.245 | 1.058 | 4.501 | 0.106 | 0.013~0.843 | 0.034 |

| Correlative factors for moderate BPD |
|-------------------------------------|
| Compared with mild BPD group        |
| PN (days)                          | 1.089  | 0.205 | 28.281 | 2.972 | 1.989~4.440 | <0.001 |
| Caffeine                           | 1.510  | 0.749 | 4.059 | 4.525 | 1.042~19.649 | 0.044 |
| Compared with severe BPD group      |
| PDA                                | −1.649 | 0.541 | 9.305 | 0.192 | 0.067~0.555 | 0.002 |
| Caffeine                           | 1.348  | 0.532 | 6.428 | 3.850 | 1.358~10.916 | 0.011 |
| Aminophylline                      | −1.821 | 0.527 | 11.948 | 0.162 | 0.058~0.455 | 0.001 |

| Correlative factors for severe BPD  |
|-------------------------------------|
| Compared with mild BPD group        |
| PN (days)                          | 1.207  | 0.214 | 31.823 | 3.343 | 2.198~5.085 | <0.001 |
| PDA                                | 2.245  | 1.058 | 4.501 | 9.441 | 1.186~75.128 | 0.034 |
| Compared with moderate BPD group    |
| PDA                                | 1.649  | 0.541 | 9.305 | 5.202 | 1.803~15.010 | 0.002 |
| Caffeine                           | −1.348 | 0.532 | 6.428 | 0.260 | 0.092~0.736 | 0.011 |
| Aminophylline                      | 1.821  | 0.527 | 11.948 | 6.179 | 2.200~17.353 | 0.001 |

Only statistically significant items are listed

BPD Bronchopulmonary dysplasia, PDA Patent ductus arteriosus, PN Parenteral nutrition, aOR Adjusted odds ratio, 95% CI 95% confidence interval
Conclusions
Severe or moderate BPD can be avoided by shortening duration of parenteral nutrition, early treatment of PDA, reducing use of aminophylline and rational use of caffeine.

Abbreviations
ARDS: Acute respiratory distress syndrome; BPD: Bronchopulmonary dysplasia; FiO2: Fraction of inspired oxygen; GA: Gestational age; GDM: Gestational diabetes mellitus; HDCP: Hypertensive disorder complicating pregnancy; NEC: Necrotizing enterocolitis; NRDS: Neonatal respiratory distress syndrome; PDA: Patent ductus arteriosus; PROM: Premature rupture of membranes; PS: Pulmonary surfactant; ROP: Retinopathy of prematurity; SAG: Small for gestational age.

Acknowledgements
None.

Authors’ contributions
J.H Yang and C.H. Tang conceptualized and designed this study. T.F. Dong, L. Liang, F. Xu, Y.F. He, C.L. Li, F. Luo and J.H. Liang were responsible for collecting data. T.T. Yang, Q.Q. Shen and S.Y. Wang were responsible for analyzing and interpretation of data. T.T. Yang and Q.Q. Shen drafted the initial manuscript, and T.T. Yang, S.Y. Wang, J.H Yang and C.H. Tang reviewed and revised the manuscript. J.H Yang and C.H. Tang approved the final manuscript submitted, and agreed to be responsible for all aspects of the work. The author(s) read and approved the final manuscript.

Funding
This study is supported by National Natural Science Foundation of China (Grant No. 81860281), Top Experts training Project for the Academy and Technology in Kunming City and Yunnan province (20170504), Research project of Health Commission of Yunnan Province (Grant No. 2018NS5234), Research project of Health Commission of Yunnan Province (Grant No. 2017NS213) and Research project of Yunnan Clinical Medical Center (2020LCZXKF -XY10). The funders were not involved in the study design, data collection, analysis, interpretation, or manuscript preparation.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Ethics committee of The First People's Hospital of Yunnan Province (Ethic number: KHLL2021-KY001). Informed consent was waived due to the retrospective nature of this study.

Consent for publication
Not applicable.

Competing interests
None.

Author details
1The Affiliated Hospital of College of Medicine, Kunming University of Science and Technology, Kunming, Yunnan, China. 2Department of Pediatrics, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, China. 3College of Medicine, Dali University, Dali, Yunnan, China. 4The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China. 5The First Clinical Medical College, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan, China. 6The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China. 7Yunnan Province Clinical Center for Hematologic Disease, Kunming, Yunnan, China.

References
1. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276(7):357–68.
2. Joebe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Resp Crit Care Med. 2001;163(7):1723–9.
3. Horbar JD, Edwards EM, Greenberg LT, et al. Variation in performance of neonatal intensive care units in the United States. JAMA Pediatr. 2017;171(3):e164396.
4. Stoll BJ, Hansen NL, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA. 2015;314(10):1039–51.
5. Stoll BJ, Hansen NL, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;126(3):443–56.
6. Ferré C, Callaghan W, Olson C, et al. Effects of maternal age and age-specific preterm birth rates on overall preterm birth rates - United States, 2007 and 2014. MMWR Morb Mortal Wkly Rep. 2016;65(43):1181–4.
7. García-Muñoz Rodrigo F, Losada Martínez A, Elorza Fernández MD, et al. The burden of respiratory disease in very-low-birth-weight infants: changes in perinatal care and outcomes in a decade in Spain. Neonatology. 2017;112(1):30–9.
8. Li PP, Zhao W. Definition evolution and epidemiological characteristics of bronchopulmonary dysplasia in premature infants. Chin J Neonatol. 2020;35(5):385–8.
9. Doyle LW, Carse E, Adams AW, et al. Ventilation in extremely preterm infants and respiratory function at 8 years. N Engl J Med. 2017;377(4):329–37.
10. Younge N, Goldstein RF, Bann CM, et al. Survival and neurodevelopmental outcomes among periviable infants. N Engl J Med. 2017;376:617–28.
11. de Jesus LC, Pappas A, Shankaran S, et al. Risk factors for post-neonatal intensive care unit discharge mortality among extremely low birth weight infants. J Pediatr. 2012;161:70–4.
12. Cheong JLY, Doyle LW. An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia. Semin Perinatol. 2018;42:478–84.
13. Álvarez-Fuente M, Arruza L, Muro M, et al. The economic impact of prematurity and bronchopulmonary dysplasia. Eur J Pediatr. 2017;176:1587–93.
14. Jackson W, Hornik CP, Messina JA, et al. In-hospital outcomes of premature infants with severe bronchopulmonary dysplasia. J Perinatol. 2017:37(7):853–6.
15. Kim DH, Kim HS, Choi CW, et al. Risk factors for pulmonary artery hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia. Neonatology. 2012;101(1):40–6.
16. Leary S, Das P, Ponnalagud D, et al. Genetic strain and sex differences in a hypoxia-induced mouse model of varying severity of bronchopulmonary dysplasia. Am J Pathol. 2019;189(5):999–1014.
17. Bose C, van Marter LJ, Laughon M, et al. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. Pediatrics. 2009;124(3):e450–8.
18. Hartling L, Liang Y, Lacaze-Masmonteil T, Choriammoniitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2012;97(1):F8–F17.
19. Antonucci R, Contu P, Porcella A, et al. Intratracheal smoke exposure: a new risk factor for bronchopulmonary dysplasia? J Perinat Med. 2004;32(3):272–7.
20. Kalikoff Thékivevedu R, Guaman MC, Shivanna B. Bronchopulmonary dysplasia: a review of pathogenesis and pathophysiology. Respir Med. 2017;132:170–7.
21. Sehgal A, Gwini SM, Menahem S, et al. Preterm growth restriction and bronchopulmonary dysplasia: the vascular hypothesis and related physiology. J Physiol. 2019;597(4):1209–20.
22. Noble S, Marchionni P, Carnelli VP. Neonatal outcome of small for gestational age preterm infants. Eur J Pediatr. 2017;176(8):1083–8.
23. Li WL, Xu FL, Niu M, et al. Clinical features and prognosis of preterm infants with varying degrees of bronchopulmonary dysplasia. Zhonguo Dang Dai Er Ke Za Zhi. 2018;20(4):262–6.
24. Kim SH, Han YS, Chun J, et al. Risk factors that affect the degree of bronchopulmonary dysplasia: comparison by severity in the same gestational age. PLoS One. 2020;15(7):e0235901.
25. Jensen EA, Foglia EE, Dysart KC, et al. Adverse effects of small for gestational age differ by gestational week among very preterm infants. Arch Dis Child Fetal Neonatal Ed. 2019;104(2):F192–8.
26. Zhang WW, Yu YH, Dong XY, et al. Treatment status of extremely premature infants with gestational age < 28 weeks in a Chinese perinatal center from 2010 to 2019. World J Pediatr. 2022;18(1):67–74.
27. Rayan M, Devlieger H, Jochum F, et al. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J Parenter Enteral Nutr. 2012;36(1 Suppl):S15–945.
28. Milanesi BG, Lima PA, Villela LD, et al. Assessment of early nutritional intake in preterm infants with bronchopulmonary dysplasia: a cohort study. Eur J Pediatr. 2021;180(5):1423–30.
29. Al-Jebawi Y, Agarwal N, Groh Wargo S, et al. Low caloric intake and high fluid intake during the first week of life are associated with the severity of bronchopulmonary dysplasia in extremely low birth weight infants. J Neonatal Perinatal Med. 2020;13(2):207–14.
30. Härkin P, Marttila R, Pokka T, et al. Morbidities associated with patent ductus arteriosus in preterm infants. Nationwide cohort study. J Matern Fetal Neonatal Med. 2018;31(19):2576–83.
31. Olsson KW, Youssef S, Kjellberg M, et al. A matched case control study of surgically and non-surgically treated patent ductus arteriosus in extremely preterm infants. Front Pediatr. 2021;9:648372.
32. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–21.
33. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893–902.
34. Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev. 2010;(12):CD000140. https://doi.org/10.1002/14651858.CD000140.pub2.
35. Lamba V, Winners O, Fort P. Early high-dose caffeine improves respiratory outcomes in preterm infants. Children (Basel). 2021;8(6):501.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.